Clinical trials: Eosinophilic Asthma
Severe Eosinophilic Asthma
Study to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in Spain
Observational, retrospective study in adults (≥18 years) with severe asthma (maintenance treatment with high dose inhaled corticosteroids combined with long-acting agonist β2) and eosinophilic phenotype, who at the discretion of…
- Trial name
- ORBE (NCT04126499)
- Where
- Spain
- Volunteers
- 28 people
- Sponsor
- AstraZeneca
Asthma
A Study of Depemokimab in Participants of 6 to 11 Years of Age
This study is aimed at assessing depemokimab as an add-on medicine for the treatment of asthma with type-2 inflammation in participants of 6 to 11 years of age.
- Trial name
- GLIDE (NCT07671001)
- Testing
- Depemokimab
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Asthma; Eosinophilic
Effect of Mepolizumab on Decrease of Systemic Corticosteroids in Patients With Severe Eosinophilic Asthma
The primary objective of the study is to measure the effect of mepolizumab on declines in oral corticosteroid therapy (prednisolone or prednisone) in patients with severe eosinophilic asthma.
- Trial name
- Mepolizumab (NCT03453021)
- Testing
- Mepolizumab
- Where
- France
- Volunteers
- 27 people
- Sponsor
- University Hospital, Grenoble
Eosinophilic Asthma
Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma
This is a proof of concept study designed to assess the effects of a single intravenous dose of etokimab compared to placebo in adult participants with severe eosinophilic asthma.
- Trial name
- NCT03469934
- Testing
- Etokimab
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 25 people
- Sponsor
- AnaptysBio, Inc.
Asthma
Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients
Primary objective of the study is to evaluate whether patients with severe eosinophilic asthma who have received long-term treatment with mepolizumab (at least 3 years) need to maintain treatment with mepolizumab to continue to…
- Trial name
- NCT02555371
- Testing
- Mepolizumab 100mg
- Where
- 73 sites in United States, Argentina and 12 more
- Volunteers
- 306 people
- Sponsor
- GlaxoSmithKline
Asthma; Eosinophilic
Functional Lung MRI for Early Treatment Response Assessment for Patients With Eosinophilic Asthma
Patients with severe eosinophilic asthma will be placed on biologics if they continue to be uncontrolled despite maximized inhalation therapy or if they are only controlled under oral corticosteroids.
- Trial name
- FUNLUM (NCT04512521)
- Testing
- Mepolizumab
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Hannover Medical School
Severe Asthma
Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients
This study aims to generate real-world data on the characteristics of patients receiving benralizumab to assess early PRO parameters as well as long-term treatment effects in the Gulf cooperative council (Kingdom of Saudi Arabia…
- Trial name
- iOUTRUN (NCT05603845)
- Where
- 24 sites in Colombia, Dominican Republic and 6 more
- Volunteers
- 291 people
- Sponsor
- AstraZeneca
Asthma
Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
Reslizumab is a type of medicine called a monoclonal antibody that is made in the research clinic; it works by blocking a specific protein in the body called interleukin-5.
- Trial name
- RITE (NCT02947945)
- Testing
- Reslizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Jewish Health
Severe Eosinophilic Asthma
A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy
This is an observational, multicenter, prospective study on patients with severe eosinophilic asthma treated with benralizumab aimed at evaluating the achievement of partial and complete clinical remission.
- Trial name
- ATHENA (NCT07214753)
- Testing
- benralizumab
- Where
- 28 sites in Italy
- Volunteers
- 335 people
- Sponsor
- AstraZeneca
Eosinophilic Esophagitis
24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)
This is a 24-week randomized, double-blind, placebo-controlled induction study of APT-1011 in adults (≥18 years old) with eosinophilic esophagitis (EoE) followed by a single-arm, open-label extension.
- Trial name
- NCT05634746
- Testing
- APT-1011, Esophagogastroduodenoscopy
- Where
- 60 sites in United States, Canada
- Volunteers
- 218 people
- Sponsor
- Ellodi Pharmaceuticals, LP
Chronic Rhinosinusitis With Nasal Polyps
Real Life Study of Biologicals in Patients With Severe CRSwNP
This study is a pragmatic, real-life, observational study recruiting adult patients with chronic rhinosinusitis with nasal polyposis who are eligible to start biologicals as standard treatment.
- Trial name
- NASUMAB (NCT05938972)
- Testing
- Mepolizumab
- Where
- Belgium
- Volunteers
- 180 people
- Sponsor
- University Hospital, Ghent
Eosinophilic Asthma, Asthma; Eosinophilic
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.
This study will assess the efficacy and safety of dexpramipexole as an adjunctive oral therapy in participants with inadequately controlled asthma with an eosinophilic phenotype and a history of asthma exacerbations.
- Conditions
- Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
- Trial name
- EXHALE-2 (NCT05763121)
- Testing
- Dexpramipexole Dihydrochloride
- Where
- 401 sites in United States, Argentina and 18 more
- Volunteers
- 1,061 people
- Sponsor
- Areteia Therapeutics
Asthma With Eosinophilic Phenotype
A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil Phenotype
The purpose of this study is to evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients with Eosinophil Phenotype.
- Trial name
- NCT05522439
- Testing
- SHR-1703
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Asthma
Retrospective Analysis of Systemic Glucocorticoid Mediated Long-term Effects, Patient Pathways and Economic Burden Across Multiple Indications
Glucocorticoids are important in the treatment of many inflammatory, allergic, immunologic, and malignant disorders. However, the adverse effects of systemic corticosteroids are one of the most common causes of iatrogenic…
- Trial name
- NCT06488703
- Where
- Germany
- Volunteers
- 107,032 people
- Sponsor
- GlaxoSmithKline
ALLERGIC ASTHMA
A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy
The researcher proposes to assess levels of sputum inflammatory markers (eosinophils, eosinophil cationic protein (ECP), neutrophils IL-8) before and while on anti-IgE therapy in a pediatric population of moderate to severe…
- Trial name
- NCT00283504
- Testing
- ANTI-IGE THERAPY (XOLAIR)
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of The King's Daughters
Severe Asthma
Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma.
Pragmatic trial to define the magnitude and the predictive factors of the response to omalizumab and mepolizumab in adult patients with severe refractory asthma and eligible to both therapies.
- Trial name
- PREDICTUMAB (NCT03476109)
- Testing
- Randomisation to omalizumab, Randomisation to mepolizumab
- Where
- 13 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Asthma, Bronchial
A Non-interventional, Prospective Study With Benralizumab
This is a prospective, non-interventional, single-arm, multicenter study to investigate asthma control, and health-related quality of life (HRQL), lung function and asthma medication intake in severe eosinophilic asthma patients…
- Trial name
- AIR POWER (NCT06422078)
- Where
- 41 sites in Germany
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Asthma
GB001 in Adult Subjects With Moderate to Severe Asthma
A randomized, double-blind, placebo-controlled, dose-ranging, multi-center study to evaluate the efficacy and safety of GB001 when added to standard-of care (SOC) asthma maintenance therapy in adults with moderate to severe…
- Trial name
- NCT03683576
- Testing
- GB001
- Where
- 117 sites in United States, Austria and 9 more
- Volunteers
- 481 people
- Sponsor
- GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
Eosinophils, Asthma
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
This is a multicenter, open-label (OL) extension study to obtain additional long-term safety data for subcutaneous (sc) administration of reslizumab treatment administered at a fixed dose of 110 mg in patients 12 years of age and…
- Trial name
- NCT03052725
- Testing
- reslizumab
- Where
- 134 sites in United States, Belgium and 11 more
- Volunteers
- 391 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Allergy, Asthma
Evaluation and Long-Term Follow-Up of Patients With Allergic and Inflammatory Disorders
This study will evaluate and follow patients with various allergic, hypersensitivity and inflammatory disorders. The protocol is not designed to test new treatments; patients will be managed with standard of care therapies.
- Conditions
- Allergy, Asthma, Allergic Rhinitis, Mastocytosis
- Trial name
- NCT00557895
- Where
- United States
- Volunteers
- 288 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)